Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Uptake and biodistribution of 89Zr-ipilimumab in metastatic melanoma
2012-003616-31Phase 2Active
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ipilimumab in melanoma, sponsored by Amsterdam University Medical Center. Primary endpoint: Tumor uptake and biodistribution of 89Zr-ipilimumab. Started Aug 2015; status: active.
02
Drugs
ipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2012-003616-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003616-31.